To rapidly accelerate the development of drugs to prevent, treat and cure Alzheimer's disease.
Alzheimer's Drug Discovery Foundation focuses on speeding up drug development for Alzheimer’s disease, with a grantmaking model built around translational research rather than broad general support. Its recent awards show a strong emphasis on companies and research institutions working on diagnostics, biomarkers, prevention, and early-stage therapeutics. The largest listed grant went to Alamar Biosciences for Alzheimer’s research, and other major awards supported C2N Diagnostics and Curasen Therapeutics Inc. Across the recent-grants list, the foundation backs work that moves from discovery into validation, including biomarker development, clinical-trial enabling research, and therapeutic pipelines. That pattern fits the foundation’s stated priorities in biomarkers, clinical trials, prevention, neuroinflammation, tau, amyloid-related research, and aging biology. Recent recipients also include institutions such as The Scripps Research Institute and Cleveland Clinic Foundation, showing support for both academic and industry-led research. The grantmaking style is highly targeted, with large awards aimed at specific scientific milestones in Alzheimer’s and related dementias.
A major part of the foundation’s portfolio centers on biomarker science. It gave $5,609,700 to Pharmatrophix for Alzheimer’s research, and it also supports biomarker development programs for neuroimaging and cerebrospinal fluid work. Prevention is another clear theme: the foundation awarded $3,247,762 to University of Nevada Las Vegas for Alzheimer’s research, alongside a prevention-focused funding stream for clinical trials, comparative effectiveness research, and epidemiological studies. Therapeutic development also features prominently. It gave $5,000,000 to Coya Therapeutics for Alzheimer’s research and $4,845,794 to Modulo Bio Inc for Alzheimer’s research, reflecting support for translational programs that move toward early-stage clinical testing. The foundation also funds research dissemination and scientific community-building through prize and conference-related programs.
Typical awards are large: the 25th percentile is $213,088, the median is $600,000, and the 75th percentile is $1,822,405. The recent-grants list shows repeat funding to the same recipient in different years, including Davos Alzheimers Collaborative in both 2024 and 2025, which points to ongoing project support rather than one-time awards only. The foundation is a regular funder, not a fund for individuals, and it does not make program-related investments. Its active programs include several unsolicited RFPs, especially in therapeutics, prevention, and biomarker development, alongside a prize program that is invitation- or selection-based rather than open application.
$54.8M
$299.4M
$47.3M
$88.3M
Most grants fall between $213K and $1.8M, with a median of $600K.
25th Percentile
$213K
Median
$600K
75th Percentile
$1.8M
About 5% of grants go to recipients in CT.
HOWARD FILLIT MD
Sign up for a free Kindora account to access AI-generated insights into this funder's giving patterns, decision-makers, and fit signals.
Get Started FreeFree Kindora accounts unlock side-by-side comparisons with foundations that share this funder's focus areas and giving profile.
Get Started FreeSign up free to see how well your nonprofit fits this funder, get an AI-generated pitch, and unlock similar foundations.
Grantmaking is national, and every recipient in the provided country distribution is in the United States. The top state by grant count is Connecticut, while only 4% of grants go to recipients in the foundation’s headquarters state of New York. Recent awards are spread across major research hubs, including Cambridge, Boston, San Diego, and Philadelphia. California appears frequently through recipients in Fremont, San Carlos, Menlo Park, San Francisco, and La Jolla, showing a strong West Coast concentration alongside East Coast research centers.
The foundation focuses on Alzheimer’s disease drug discovery and development, with support for biomarkers, clinical trials, prevention, neuroinflammation, tau, amyloid-related research, and aging biology. Its active programs also include neuroimaging and CSF biomarker RFPs, drug development RFPs, and prevention-focused funding for clinical trials and epidemiological studies.
Yes, several active programs accept unsolicited applications. That includes the Neuroimaging and CSF Biomarker RFP, the Prevention RFP, and the Drug Development RFP, each listed as accepting unsolicited submissions. The prize and biobank-sharing programs are not open to unsolicited applications.
Typical grants are substantial: the 25th percentile is $213,088, the median is $600,000, and the 75th percentile is $1,822,405. Active program ranges also reach from $100,000 to $3,000,000 for therapeutics and biomarker RFPs.
Yes. Davos Alzheimers Collaborative appears twice in the recent-grants list, with awards of $2,500,000 in both 2024 and 2025. That suggests the foundation supports some recipients across multiple years.
The recent-grants list shows funding to academic centers, biotechnology companies, and research institutions. Examples include The Scripps Research Institute, Cleveland Clinic Foundation, and University of Nevada Las Vegas, alongside companies working on Alzheimer’s research and diagnostics.
2025
Source: IRS Form 990-PF, fiscal year 2025.
Most recent grants reported to the IRS.
| Recipient | Location | Amount | Year | Purpose |
|---|---|---|---|---|
| ALAMAR BIOSCIENCES | FREMONT, CA | $10,016,094 | 2025 | ALZHEIMERS RESEARCH |
| C2N DIAGNOSTICS | ST LOUIS, MO | $7,025,121 | 2025 | ALZHEIMERS RESEARCH |
| PHARMATROPHIX | MENLO PARK, CA | $5,609,700 | 2025 | ALZHEIMERS RESEARCH |
| METRO INTERNATIONAL BIOTECHEDENROC | CAMBRIDGE, MA | $5,000,000 | 2025 | ALZHEIMERS RESEARCH |
| COYA THERAPEUTICS | HOUSTON, TX | $5,000,000 | 2025 | ALZHEIMERS RESEARCH |
| MODULO BIO INC | SAN DIEGO, CA | $4,845,794 | 2025 | ALZHEIMERS RESEARCH |
| UNIVERSITY OF NEVADA LAS VEGAS | LAS VEGAS, NV | $3,247,762 | 2025 | ALZHEIMERS RESEARCH |
| AQUINNAH PHARMACEUTICALS | CAMBRIDGE, MA | $2,999,586 | 2025 | ALZHEIMERS RESEARCH |
| DAVOS ALZHEIMERS COLLABORATIVE | PHILADELPHIA, PA | $2,500,000 | 2025 | ALZHEIMERS RESEARCH |
| UNIVERSITY OF ARIZONA - HEALTH SCIENCES | TUCSON, AZ | $1,774,201 | 2025 | ALZHEIMERS RESEARCH |
| VACCINEX | ROCHESTER, NY | $1,750,000 | 2025 | ALZHEIMERS RESEARCH |
| VIEWMIND | NEW YORK, NY | $1,429,119 | 2025 | ALZHEIMERS RESEARCH |
| ESYA INC | FRISCO, TX | $789,000 | 2025 | ALZHEIMERS RESEARCH |
| TRUSTEES OF INDIANA UNIVERSITY | BLOOMINGTON, IN | $599,920 | 2025 | ALZHEIMERS RESEARCH |
| UNIVERSITY OF MINNESOTA | BROOKLINE, MA | $493,875 | 2025 | ALZHEIMERS RESEARCH |
| CLEARVIEW HEALTHCARE PARTNERS | NEW YORK, NY | $272,000 | 2025 | ALZHEIMERS RESEARCH |
| JOHNS HOPKINS UNIVERSITY | BALTIMORE, MD | $269,967 | 2025 | ALZHEIMERS RESEARCH |
| UNIVERSITY OF KANSAS MEDICAL CENTER | KANSAS CITY, KS | $250,000 | 2025 | ALZHEIMERS RESEARCH |
| NEUROTHERAPIA INC | GATES MILLS, OH | $250,000 | 2025 | ALZHEIMERS RESEARCH |
| NEUROAGE THERAPEUTICS | SAN FRANCISCO, CA | $249,817 | 2025 | ALZHEIMERS RESEARCH |
| MTI BIOTECH INC | AMES, IA | $158,576 | 2025 | ALZHEIMERS RESEARCH |
| TRUSTEES OF BOSTON UNIVERSITY | BOSTON, MA | $150,000 | 2025 | ALZHEIMERS RESEARCH |
| USAGAINSTALZHEIMER'S NETWORK | WASHINGTON, DC | $65,000 | 2025 | ALZHEIMERS RESEARCH |
| THE MILKEN INSTITUTE | NEW YORK, NY | $25,000 | 2025 | ALZHEIMERS RESEARCH |
| GLOBAL ALZHEIMER'S PLATFORM FOUNDATION | WASHINGTON, DC | $20,000 | 2025 | ALZHEIMERS RESEARCH |
| MOBILITY CONSULTING GROUP LLC | ALPHARETTA, GA | $9,992 | 2025 | ALZHEIMERS RESEARCH |
| CURASEN THERAPEUTICS INC | SAN CARLOS, CA | $5,814,712 | 2024 | ALZHEIMERS RESEARCH |
| METRO INTERNATIONAL BIOTECH | CAMBRIDGE, MA | $5,750,000 | 2024 | ALZHEIMERS RESEARCH |
| THERINI BIO | SAN FRANCISCO, CA | $5,000,000 | 2024 | ALZHEIMERS RESEARCH |
| APRINOIA THERAPEUTICS INC | CAMBRIDGE, MA | $4,357,900 | 2024 | ALZHEIMERS RESEARCH |
| DAVOS ALZHEIMERS COLLABORATIVE | PHILADELPHIA, PA | $2,500,000 | 2024 | ALZHEIMERS RESEARCH |
| ALZPATH INC | CARLSBAD, CA | $1,910,202 | 2024 | ALZHEIMERS RESEARCH |
| CLEVELAND CLINIC FOUNDATION | CLEVELAND, OH | $1,828,343 | 2024 | ALZHEIMERS RESEARCH |
| ASTROCYTE PHARMACEUTICALS INC | GROTON, CT | $1,000,000 | 2024 | ALZHEIMERS RESEARCH |
| STARTUP HEALTH LLC | NEW YORK, NY | $975,875 | 2024 | ALZHEIMERS RESEARCH |
| TRUSTEES OF BOSTON UNIVERSITY | BOSTON, MA | $844,286 | 2024 | ALZHEIMERS RESEARCH |
| NEURODEX | NATICK, MA | $750,000 | 2024 | ALZHEIMERS RESEARCH |
| CICARDIC LLC | ARLINGTON, MA | $675,890 | 2024 | ALZHEIMERS RESEARCH |
| VIRGINIA COMMONWEALTH UNIVERSITY | RICHMOND, VA | $600,000 | 2024 | ALZHEIMERS RESEARCH |
| TUFTS MEDICAL CENTER | BOSTON, MA | $599,788 | 2024 | ALZHEIMERS RESEARCH |
| CASE WESTERN RESERVE UNIVERSITY | CLEVELAND, OH | $599,259 | 2024 | ALZHEIMERS RESEARCH |
| WAKE FOREST UNIVERSITY | WINSTON SALEM, NC | $589,379 | 2024 | ALZHEIMERS RESEARCH |
| AMPRION INC | SAN FRANCISCO, CA | $570,750 | 2024 | ALZHEIMERS RESEARCH |
| BRAINSCOPE COMPANY INC | BETHESDA, MD | $491,086 | 2024 | ALZHEIMERS RESEARCH |
| MILKEN INSTITUTE | AMES, IA | $250,000 | 2024 | CONFERENCE SPONSORSHIP |
| PELAGOS PHARMACEUTICALS | CAMBRIDGE, MA | $214,118 | 2024 | ALZHEIMERS RESEARCH |
| UNIVERSITY OF CALIFORNIA IRVINE | IRVINE, CA | $175,000 | 2024 | ALZHEIMERS RESEARCH |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | WASHINGTON, DC | $73,700 | 2024 | ALZHEIMERS RESEARCH |
| USAGAINSTALZHEIMER'S | WASHINGTON, DC | $35,000 | 2024 | ALZHEIMERS RESEARCH |
| FOUNDATION FOR THE NATIONAL INSTITUTE OF HEALTH | NORTH BETHESDA, MD | $30,000 | 2024 | ALZHEIMERS RESEARCH |
ALAMAR BIOSCIENCES
$10,016,094ALZHEIMERS RESEARCH
C2N DIAGNOSTICS
$7,025,121ALZHEIMERS RESEARCH
PHARMATROPHIX
$5,609,700ALZHEIMERS RESEARCH
METRO INTERNATIONAL BIOTECHEDENROC
$5,000,000ALZHEIMERS RESEARCH
COYA THERAPEUTICS
$5,000,000ALZHEIMERS RESEARCH
MODULO BIO INC
$4,845,794ALZHEIMERS RESEARCH
UNIVERSITY OF NEVADA LAS VEGAS
ALZHEIMERS RESEARCH
AQUINNAH PHARMACEUTICALS
$2,999,586ALZHEIMERS RESEARCH
DAVOS ALZHEIMERS COLLABORATIVE
$2,500,000ALZHEIMERS RESEARCH
UNIVERSITY OF ARIZONA - HEALTH SCIENCES
$1,774,201ALZHEIMERS RESEARCH
VACCINEX
$1,750,000ALZHEIMERS RESEARCH
VIEWMIND
$1,429,119ALZHEIMERS RESEARCH
ESYA INC
$789,000ALZHEIMERS RESEARCH
TRUSTEES OF INDIANA UNIVERSITY
$599,920ALZHEIMERS RESEARCH
UNIVERSITY OF MINNESOTA
$493,875ALZHEIMERS RESEARCH
CLEARVIEW HEALTHCARE PARTNERS
$272,000ALZHEIMERS RESEARCH
JOHNS HOPKINS UNIVERSITY
$269,967ALZHEIMERS RESEARCH
UNIVERSITY OF KANSAS MEDICAL CENTER
$250,000ALZHEIMERS RESEARCH
NEUROTHERAPIA INC
$250,000ALZHEIMERS RESEARCH
NEUROAGE THERAPEUTICS
$249,817ALZHEIMERS RESEARCH
MTI BIOTECH INC
$158,576ALZHEIMERS RESEARCH
TRUSTEES OF BOSTON UNIVERSITY
$150,000ALZHEIMERS RESEARCH
USAGAINSTALZHEIMER'S NETWORK
$65,000ALZHEIMERS RESEARCH
THE MILKEN INSTITUTE
$25,000ALZHEIMERS RESEARCH
GLOBAL ALZHEIMER'S PLATFORM FOUNDATION
$20,000ALZHEIMERS RESEARCH
MOBILITY CONSULTING GROUP LLC
$9,992ALZHEIMERS RESEARCH
CURASEN THERAPEUTICS INC
$5,814,712ALZHEIMERS RESEARCH
METRO INTERNATIONAL BIOTECH
$5,750,000ALZHEIMERS RESEARCH
THERINI BIO
$5,000,000ALZHEIMERS RESEARCH
APRINOIA THERAPEUTICS INC
$4,357,900ALZHEIMERS RESEARCH
DAVOS ALZHEIMERS COLLABORATIVE
$2,500,000ALZHEIMERS RESEARCH
ALZPATH INC
$1,910,202ALZHEIMERS RESEARCH
CLEVELAND CLINIC FOUNDATION
$1,828,343ALZHEIMERS RESEARCH
ASTROCYTE PHARMACEUTICALS INC
$1,000,000ALZHEIMERS RESEARCH
STARTUP HEALTH LLC
$975,875ALZHEIMERS RESEARCH
TRUSTEES OF BOSTON UNIVERSITY
$844,286ALZHEIMERS RESEARCH
NEURODEX
$750,000ALZHEIMERS RESEARCH
CICARDIC LLC
$675,890ALZHEIMERS RESEARCH
VIRGINIA COMMONWEALTH UNIVERSITY
$600,000ALZHEIMERS RESEARCH
TUFTS MEDICAL CENTER
$599,788ALZHEIMERS RESEARCH
CASE WESTERN RESERVE UNIVERSITY
$599,259ALZHEIMERS RESEARCH
WAKE FOREST UNIVERSITY
$589,379ALZHEIMERS RESEARCH
AMPRION INC
$570,750ALZHEIMERS RESEARCH
BRAINSCOPE COMPANY INC
$491,086ALZHEIMERS RESEARCH
MILKEN INSTITUTE
$250,000CONFERENCE SPONSORSHIP
PELAGOS PHARMACEUTICALS
$214,118ALZHEIMERS RESEARCH
UNIVERSITY OF CALIFORNIA IRVINE
$175,000ALZHEIMERS RESEARCH
BIOTECHNOLOGY INNOVATION ORGANIZATION
$73,700ALZHEIMERS RESEARCH
USAGAINSTALZHEIMER'S
$35,000ALZHEIMERS RESEARCH
FOUNDATION FOR THE NATIONAL INSTITUTE OF HEALTH
$30,000ALZHEIMERS RESEARCH
Current and upcoming funding from Alzheimer'S Drug Discovery Foundation that your nonprofit may be able to apply for.
Who can apply: Eligibility details were not provided in the scraped content. The program appears to be an application-based partner funding opportunity.
Deadline: Full proposal due August 17, 2026; LOI deadline has passed.
Who can apply: Academic centers and biotechnology companies worldwide advancing therapeutic and biomarker development for Alzheimer’s and related dementias; terms vary by RFP and use mission-related investments (returns expected for some awards).
Deadline: Letter of Intent: 2026-09-14 (5:00 pm ET). Invited Full Proposal: TBD
Who can apply: Academic centers and biotechs worldwide advancing therapeutic development for Alzheimer's and related dementias; funding is milestone-based mission-related investment.
Deadline: Applications are reviewed throughout the year; current opening noted on funding opportunities page with LOI due September 14, 2026 for therapeutic programs
Who can apply: Open to academic institutions and biotechnology companies worldwide working on biomarker development for Alzheimer's disease and related dementias. Funding is through ADDF mission-related investments tied to milestones.
Deadline: Letter of Intent due September 14, 2026; invited full proposal TBD.
Who can apply: Open to academic institutions and biotechnology companies worldwide pursuing prevention-oriented programs for Alzheimer's disease and related dementias. Awards are mission-related investments with milestone-based terms.
Deadline: Letter of Intent due September 14, 2026; invited full proposal TBD.
Who can apply: Projects testing prevention approaches or whether drug use/choice affects dementia risk. See RFP for details.
Who can apply: Open to academic centers and biotechs advancing therapeutic and biomarker development for Alzheimer's and related dementias. Specific eligibility varies by RFP.
Deadline: Letter of Intent: September 14, 2026; Invited Full Proposal: TBD
Track these deadlines, get reminders, and see how well your nonprofit fits — free with a Kindora account.
Create a free accountDeadlines and eligibility are summarized from public sources and may change — always confirm the details on the funder's official application page before applying.
